Yong-Oon Ahn
Overview
Explore the profile of Yong-Oon Ahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Sim S, Beom S, Ahn Y, Keam B, Kim T, Lee S, et al.
Thorac Cancer
. 2016 Apr;
7(2):161-6.
PMID: 27042217
Background: The neutrophil-lymphocyte ratio (NLR) is a marker of poor prognosis in lung cancer patients. However, previous data have been based on an heterogeneous population of lung cancer patients and...
22.
Yang Y, Lim O, Kim T, Ahn Y, Choi H, Chung H, et al.
Cancer Immunol Res
. 2016 Jan;
4(3):215-24.
PMID: 26787822
Natural killer (NK) cells with mismatched killer cell immunoglobulin-like receptor-ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. Ex vivo-expanded and highly activated NK cells...
23.
Kim T, Song A, Kim D, Kim S, Ahn Y, Keam B, et al.
J Thorac Oncol
. 2015 Oct;
10(12):1736-44.
PMID: 26473643
Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with...
24.
Ahn Y, Weeres M, Neulen M, Choi J, Kang S, Heo D, et al.
Eur J Immunol
. 2015 Jun;
45(8):2335-42.
PMID: 26046454
Death receptor 3 (DR3, TNFRSF25) is expressed by activated lymphocytes and signaling by its ligand, TL1A, enhances cytokine expression and proliferation. Recent studies show that DR3 is also present on...
25.
Keam B, Kim S, Ahn Y, Kim T, Lee S, Kim D, et al.
Anticancer Res
. 2015 Jan;
35(1):175-82.
PMID: 25550549
Background/aim: The purpose of the present study was to explore the antiproliferative effect of BYL719, a specific inhibitor for phosphatidylinositol 3-kinase (PI3K) p110α, in human head and neck cancer cell...
26.
Weeres M, Robien K, Ahn Y, Neulen M, Bergerson R, Miller J, et al.
J Immunol
. 2014 Aug;
193(7):3456-62.
PMID: 25149465
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] is the biologically active form of vitamin D and is immunoregulatory. 1,25(OH)2D3 binds the vitamin D receptor complex present in many immune populations and can illicit transcriptional...
27.
Kim J, Koh Y, Kim D, Ahn Y, Kim T, Han S, et al.
Cancer Res Treat
. 2014 Jan;
45(4):325-33.
PMID: 24454005
Purpose: Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated. Materials...
28.
Ahn Y, Kim S, Kim T, Song E, Park M, Heo D
J Immunother
. 2013 Aug;
36(7):373-81.
PMID: 23924789
Adoptive cell transfer of ex vivo-activated natural killer (NK) cells is a promising therapy for cancer treatment. Because of inhibitory signaling through killer immunoglobulin-like receptor (KIR)-KIR ligands, KIR-mismatched allogeneic NK...
29.
Kim T, Kim S, Ahn Y, Lee S, Kim D, Heo D
Leuk Lymphoma
. 2013 Jun;
55(4):940-3.
PMID: 23772641
No abstract available.
30.
Ahn Y, Blazar B, Miller J, Verneris M
Blood
. 2013 Jan;
121(12):2234-43.
PMID: 23327921
Human interleukin (IL)-22-producing RORγt(+) innate lymphoid cells (ILC22) and conventional natural killer (cNK) cells are present in secondary lymphoid tissues. Both have an immunophenotype corresponding to stage III NK progenitors...